Top Tech Companies (2,057)
Don't see your company?
Create a company profile
Apertura is a biotechnology company opening opportunities in gene therapy for treating debilitating diseases with limited options. We are pioneering next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure in New York City.
Velocity Clinical Research is an Owned Clinical Site Business comprised of 30 fully-integrated, centrally controlled research sites. Our model delivers superior accelerated enrollment and consistent, reliable results – helping our clients maintain the highest standards of care while bringing disruptive, innovative medical treatments to patients as quickly and efficiently as possible. We are driving improvement of the clinical research industry by advancing site-level productivity by further developing efficiencies that can only be achieved in an owned site model, ultimately leading to improved study execution.
Stratix Labs is a biotechnology company develops products that accelerate the development and validation of disinfectants.
BioRegenerative Sciences is a provider of therapeutic products that rejuvenate the body to produce natural health and beauty.
Stelvio Oncology is focused on delivering precision medicine diagnostics and novel therapeutics for glioblastoma.
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. The Company’s proprietary anti-inflammatory pipeline includes imsidolimab, its anti-IL-36R antibody, previously referred to as ANB019, for the treatment of dermatological inflammatory diseases, including generalized pustular psoriasis, or GPP, and moderate-to-severe hidradenitis suppurativa; rosnilimab, its anti-PD-1 agonist program, previously referred to as ANB030, for the treatment of moderate-to-severe alopecia areata; and its anti-BTLA agonist program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly) GSK4057190), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386).
Progressive Care provides prescription pharmaceuticals specializing in anti-retroviral patient management, long-term care, and DME.
Bringing Speed and Certainty to Life Sciences
Kintara Therapeutics is a developer of novel cancer therapies for patients with unmet medical needs.
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.
CUSABIO is a National High-Tech Enterprise with research, production and sales in one.
ImageWare Systems develops identity management solutions providing biometric, secure credential and law enforcement technologies.
ChemImage Corporation is committed to making the world healthier and safer through dramatic advancements in chemical imaging technologies. The company’s proprietary chemical imaging sensors, algorithms, and analysis software enable life sciences and medical device companies, defense and security organizations, and computer vision professionals to solve challenging health and safety issues. With performance-leading chemical imaging technology, ChemImage strives to provide people all over the world with an Awareness of Things® (AoT®), giving a new level of situational awareness to people in their everyday lives. For more information, visit www.chemimage.com
We produce microorganism-based, natural, and cost-effective growth medium supplement to grow muscle stem cells. Instead of conventional fetal-bovine-serum (FBS) dependent production, which is nearly 90% of the bill, our patent-pending formulation decreases related expenses dramatically. We introduce a much better way to cultivate affordable meat.
Nutriati is a food technology company focused on the research, development and commercialization of innovative plant-based food ingredients.
Inanovate was founded in Massachusetts by two Babson MBA graduates, after winning first prize at the Babson Business Plan competition. The company has since grown operations in Massachusetts, North Carolina and the UK, forming close alliances with leading commercial and academic institutions. Inanovate has combined expertise from nano-scale physics, bio-engineering, bio-chemistry and biotechnology to create a unique mutliplexed protein screening technology called Longitudinal Assay Screening (LAS), designed to help advance the development and implementation of next generation therapeutics and clinical diagnostics. Inanovate has recently completed testing and demonstration of the world's first protein detection and measurement platform to integrate LAS - The Bio-ID 400.
Over the past decade, Advanced Brain Monitoring has developed and implemented mobile, user-friendly platforms for acquiring, integrating, analyzing and reporting multi-sensor data in real-world applications. Our strong and growing technical team includes PhD- and masters-level hardware engineers, biostatisticians, software engineers and experts in signal processing, experimental design and clinical trials. ABM seeks to build on existing collaborations within the academic community and develop strategic partnerships across industry with like-minded professionals.
Aerpio Pharmaceuticals is a biotechnology company that develops small molecules and monoclonal antibodies for vascular diseases treatment.
BioDetego is developing, VASPfore, a new biomarker test for selecting cancer treatment protocols.
Alphazyme was founded in 2018 by Christopher Benoit, Stephana Petrino and Chad Decker. Our experienced team has a track record of success and a passion for supporting molecular biology innovators. Our mission is to be the world’s premier partner for custom, industrial-scale, molecular biology enzymes. We are enzyme development and production experts, and partner with the manufacturers of nucleic acid therapies and detection platforms to develop and produce affordable, reliable enzymes which meet the specifications of the rapidly expanding market for custom DNA and RNA molecules, genomic medicines and genetic tests. Consistent quality, scalable processes, and compatibility with regulatory requirements are the hallmarks of our business.
